Evidence map›Paper›PMID 38849839›Full record

ArticleRadiation oncology (London, England)2024

Xuemin Di, Zhen Gao, Huimin Yu, Xiaoli Liu, Jinxin Zhao, Juan Wang, Hongtao Zhang

Abstract read
In one paragraph

Article in Radiation oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuemin DiDepartment of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China.
Zhen GaoDepartment of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China.
Huimin YuDepartment of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China.
Xiaoli LiuDepartment of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China.
Jinxin ZhaoDepartment of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China.
Juan WangDepartment of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China.
Hongtao ZhangDepartment of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China. hongtaozhangmd@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the efficacy of

methodsBetween June 2015 and April 2022, 32 patients with 41 lesions were treated with

resultsThe median follow-up was 48.52 months (range, 4-86 months), and the 6-, 12-, and 24-month LCR was 88.0%, 63.2%, and 42.1%, respectively. The 1- and 2-year survival rates were 36% and 33%, respectively, and the median survival time was 13.26 months. No significant adverse events occurred. Multivariate regression analysis showed that tumor diameter, tumor stage, and LCR were independent factors influencing survival. ROC curve analysis showed that the area under the curve for tumor diameter and D90 were 0.765 and 0.542, respectively, with cut-off values of 5.3 cm and 108.5 Gy.

conclusionsThe present findings indicate that

Indexed as

BrachytherapyIodine RadioisotopesNeoplasm Recurrence, LocalUterine Cervical NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMiddle AgedPelvic NeoplasmsPrognosisRadiotherapy DosageRetrospective StudiesSurvival RateIodine-125Iodine RadioisotopesBrachytherapyExternal Beam RadiotherapyLocoregionalNon-central pelvic recurrence of Cervical CancerPelvic recurrence

Identifiers

PMID38849839
PMCPMC11162001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.